Astellas Pharma Global Development[Grants and Funding] - Search Results

Year	Number of Results
2018	3
2019	11
2020	10
2021	4
2022	2
2023	4
2024	2

1

Pharmacokinetics and Immunogenicity of ASP0113 in CMV-Seronegative Dialysis Patients and CMV-Seronegative and -Seropositive Healthy Subjects.

Bonate PL, Van Sant C, Cho K, Zook EC, Smith LR, Boutsaboualoy S, Ye M, Wang X, Wu R, Koester A, Rammelsberg D, Goldwater R, Marbury TC. Bonate PL, et al. Clin Pharmacol Drug Dev. 2020 May;9(4):444-455. doi: 10.1002/cpdd.792. Epub 2020 Mar 23. Clin Pharmacol Drug Dev. 2020. PMID: 32202705 Clinical Trial.

2

Species Distribution and Antifungal Susceptibilities of Aspergillus Section Fumigati Isolates in Clinical Samples from the United States.

Badali H, Cañete-Gibas C, McCarthy D, Patterson H, Sanders C, David MP, Mele J, Fan H, Wiederhold NP. Badali H, et al. J Clin Microbiol. 2022 May 18;60(5):e0028022. doi: 10.1128/jcm.00280-22. Epub 2022 Apr 11. J Clin Microbiol. 2022. PMID: 35400175 Free PMC article.

3

Undertreatment of overactive bladder among men with lower urinary tract symptoms in the United States: A retrospective observational study.

Burnett AL, Walker DR, Feng Q, Johnston KM, Lozano-Ortega G, Nimke D, Hairston JC. Burnett AL, et al. Neurourol Urodyn. 2020 Jun;39(5):1378-1386. doi: 10.1002/nau.24348. Epub 2020 May 8. Neurourol Urodyn. 2020. PMID: 32383533 Free PMC article.

4

Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non-fumigatus): A multicentre, non-interventional registry study.

Thompson GR 3rd, Garcia-Diaz J, Miceli MH, Nguyen MH, Ostrosky-Zeichner L, Young JH, Fisher CE, Clark NM, Greenberg RN, Spec A, Kovanda L, Croos-Dabrera R, Kontoyiannis DP. Thompson GR 3rd, et al. Mycoses. 2022 Feb;65(2):186-198. doi: 10.1111/myc.13412. Epub 2021 Dec 22. Mycoses. 2022. PMID: 34888961

5

A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without Gout.

Zhang F, Liu Z, Jiang L, Zhang H, Zhao D, Li Y, Zou H, Wang X, Li X, Shi B, Xu J, Yang H, Hu S, Qu S. Zhang F, et al. Rheumatol Ther. 2019 Dec;6(4):543-557. doi: 10.1007/s40744-019-00173-8. Epub 2019 Sep 17. Rheumatol Ther. 2019. PMID: 31531831 Free PMC article.

6

Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study.

Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Hairston JC. Carlson KV, et al. Low Urin Tract Symptoms. 2021 Oct;13(4):425-434. doi: 10.1111/luts.12382. Epub 2021 May 14. Low Urin Tract Symptoms. 2021. PMID: 33987973 Free PMC article.

7

Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post-marketing study.

Takahashi S, Kato D, Tabuchi H, Uno S. Takahashi S, et al. Low Urin Tract Symptoms. 2021 Jan;13(1):79-87. doi: 10.1111/luts.12335. Epub 2020 Aug 5. Low Urin Tract Symptoms. 2021. PMID: 32761776 Free PMC article.

8

Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study.

Harland RC, Klintmalm G, Jensik S, Yang H, Bromberg J, Holman J, Kumar MSA, Santos V, Larson TJ, Wang X. Harland RC, et al. Am J Transplant. 2020 Jan;20(1):159-171. doi: 10.1111/ajt.15591. Epub 2019 Oct 19. Am J Transplant. 2020. PMID: 31509331 Free article. Clinical Trial.

9

Polymerase Chain Reaction Versus Blood Culture to Detect Candida Species in High-Risk Patients with Suspected Invasive Candidiasis: The MICAFEM Study.

Nieto M, Robles JC, Causse M, Gutiérrez L, Cruz Perez M, Ferrer R, Xercavins M, Herrero E, Sirvent E, Fernández C, Anguita P, Merino P; MICAFEM Study Group, GEIPC (SEIMC) and GTEIS (SEMICYUC). Nieto M, et al. Infect Dis Ther. 2019 Sep;8(3):429-444. doi: 10.1007/s40121-019-0248-z. Epub 2019 May 24. Infect Dis Ther. 2019. PMID: 31127539 Free PMC article.

10

Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain.

Rubio-Terrés C, Aguado JM, Almirante B, Cobo J, Grau S, Salavert M, González Antona Sánchez E, López Gutiérrez C, Rubio-Rodríguez D. Rubio-Terrés C, et al. Eur J Clin Microbiol Infect Dis. 2019 Jun;38(6):1105-1111. doi: 10.1007/s10096-019-03503-4. Epub 2019 Apr 13. Eur J Clin Microbiol Infect Dis. 2019. PMID: 30989419 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

29 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year